CTRV - ContraVir Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.04
-0.08 (-7.14%)
As of 3:56PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.12
Open1.11
Bid1.04 x 1100
Ask1.05 x 900
Day's Range1.00 - 1.12
52 Week Range1.00 - 6.60
Volume389,991
Avg. Volume270,730
Market Cap11.12M
Beta1.06
PE Ratio (TTM)N/A
EPS (TTM)-1.03
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.75
Trade prices are not sourced from all markets
  • PR Newswire7 days ago

    Live Investor Conference & Webinar: NASDAQ and OTC companies to present live on July 12th

    Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , July 10, 2018 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the ...

  • PR Newswire12 days ago

    ContraVir Pharmaceuticals to Present at Virtual Investor Conference

    Live Webcast Scheduled for July 12, 2018, 10:00 AM ET, followed by Q&A EDISON, N.J. , July 5, 2018 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on ...

  • GlobeNewswire18 days ago

    ContraVir Pharmaceuticals Announces $10.8 Million in Expected Gross Proceeds from Recently Expired Rights Offering

    ContraVir Pharmaceuticals, Inc. (CTRV) (“ContraVir” or the “Company”), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today that the Company’s previously announced rights offering (“the Rights Offering”) expired on Thursday, June 28, 2018 and these rights are no longer exercisable. The Company accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in approximately $10.8 million in gross proceeds.

  • GlobeNewswire22 days ago

    ContraVir Pharmaceuticals Initiates Dosing of CRV431 in First In-Human Trial

    The randomized, partially-blinded, placebo-controlled ascending sequential dose group study will assess safety, tolerability and pharmacokinetics (PK) of CRV431 in healthy volunteers as part 1 of the first clinical study. Part two of the clinical trial will consist of a single dose of CRV431 in a drug to drug interaction study assessing the safety, tolerability and PK co-administered with Viread® (tenofovir disoproxil fumarate), and part three of the study will assess the safety, tolerability, PK and preliminary signal for antiviral efficacy of CRV431 in stable HBV patients already treated with Viread®.

  • GlobeNewswire26 days ago

    ContraVir Pharmaceuticals Announces Data on Optimized Formulation of TXL™

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today the company has chosen an optimized formulation of tenofovir exalidex (TXL™) and is ready to initiate dosing HBV patients in a dose-range finding study with the optimized formulation. TXL™ has been designed to target the liver to deliver the active drug to the reservoir where the hepatitis B virus resides.

  • GlobeNewswire27 days ago

    ContraVir Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

    EDISON, N.J., June 20, 2018-- ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus, ...

  • GlobeNewswire29 days ago

    ContraVir Pharmaceuticals to Provide Corporate, Business and Clinical Updates

    EDISON, N.J., June 18, 2018-- ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus, ...

  • GlobeNewswirelast month

    ContraVir Pharmaceuticals Announces the Approval of the IND and Initiation of the Clinical Development Program of CRV431 in the United States

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today, the initiation of the clinical development program of CRV431, pursuant to the acceptance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). With the FDA’s approval, ContraVir plans to begin a streamlined early clinical program of CRV431 to test the clinical safety and efficacy profile in healthy volunteers and HBV-infected patients in the United States.

  • GlobeNewswirelast month

    ContraVir Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record

    ContraVir Pharmaceuticals, Inc. (CTRV) (“ContraVir” or the “Company”), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), today issued a reminder to shareholders that the Record Date of its proposed rights offering is June 14, 2018. To be a shareholder of record, ownership of ContraVir stock must occur by market close of June 12, 2018 to account for settlement.

  • GlobeNewswirelast month

    ContraVir Pharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

    ContraVir Pharmaceuticals, Inc. (CTRV) (“ContraVir” or the “Company”), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), today provided an informational update to stockholders regarding its rights offering and the key dates and terms relative to the offering. Stockholders are advised to ensure they complete their open market purchases of ContraVir common stock by 5:00 PM ET on Tuesday, June 12, 2018 to be considered a stockholder of record on Thursday, June 14, 2018. Holders of the Company’s warrants issued in October 2015, April 2016 and April 2017 are also invited to participate in the rights offering on the same terms as the stockholders.

  • GlobeNewswire2 months ago

    ContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Liver Fibrosis in a Preclinical Model

    ContraVir Pharmaceuticals Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today findings from a preclinical study of CRV431 indicating that the drug, a cyclophilin inhibitor, decreased the extent of fibrosis in an animal model by 46 percent compared to vehicle control. In the treatment of HBV infections, an important objective is the reduction of liver disease including fibrosis, cirrhosis and hepatocellular carcinoma (HCC).  Previously, studies of CRV431 have demonstrated its antiviral effects via the reduction of HBV DNA, surface antigen, and other viral markers.  In the recently completed preclinical study of CRV431, mice were administered streptozotocin, followed by a high fat diet that began at three weeks of age and continued for the duration of the study.

  • GlobeNewswire2 months ago

    ContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Development and Progression of Liver Tumors in Preclinical Hepatocellular Carcinoma Study

    ContraVir Pharmaceuticals Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today new findings confirming that CRV431, a cyclophilin inhibitor, reduces the number and size of liver tumors in a hepatocellular carcinoma (HCC) mouse model. Data from the study indicate that CRV431 reduced the number of tumor nodules by 44% and reduced the overall tumor burden by 56% (composite score based on tumor number and size) compared to the vehicle control group (p=0.02). Importantly, 25% of CRV431-treated mice had no liver tumors at the end of the 10 week study, whereas all vehicle-treated mice had at least five tumors per liver.

  • GlobeNewswire2 months ago

    ContraVir Pharmaceuticals to Present at 2018 BIO International Convention

    EDISON, N.J., May 29, 2018-- ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus announced ...

  • GlobeNewswire2 months ago

    ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split

    ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV) announced today, a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 8, effective May 25, 2018 (the “Effective Date”). The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq Capital Market. The new CUSIP number for the common stock following the reverse split will be 21234W 202.

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Twenty-First Century Fox Inc (NASDAQ: FOXA ) stock ...